Sikkim Journal

Peanut Allergy Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Peanut Allergy Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

March 24
22:30 2020
Peanut Allergy Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

“Peanut Allergy- Market Insight, Epidemiology and Market Forecast -2030”

(Albany, US) DelveInsight launched a new report on “Peanut Allergy Market Insights, Epidemiology and Market Forecast-2030”.

DelveInsight’s “Peanut Allergy – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Peanut Allergy, historical and forecasted epidemiology as well as the Peanut Allergy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the facts of the report

1. As per DelveInsight estimates, total prevalent population of Peanut Allergy in the 7MM was found to be 8,640,527 in 2017.
2. As per DelveInsight analysis, it is observed that, Japan has the least number of prevalent cases (1,548,318 for 2017) of Peanut Allergy, among the 7MM.
3. The total cases of mild and moderate to severe Peanut Allergy in the US varied as 2,341,384 and 1,153,219 respectively.

Key benefits of the report

1. Peanut Allergy market report covers a descriptive overview and comprehensive insight of the Peanut Allergy epidemiology and Peanut Allergy market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Peanut Allergy market report provides insights on the current and emerging therapies.
3. Peanut Allergy market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. Peanut Allergy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Peanut Allergy market.

Request for sample pages : https://www.delveinsight.com/sample-request/peanut-allergy-market

“According to DelveInsight, most of the patients diagnosed with Peanut Allergy were male.”

Food allergy is an abnormal response to a food triggered by the body’s immune system. There are several types of immune response to food. A peanut allergy is an allergic reaction to peanuts which occurs when the human body mistakenly identifies peanuts as harmful substances. Peanut allergy is recognized as one of the most severe food allergies due to its prevalence, persistency, and the potential severity of the allergic reaction. Although other food allergies occurring in childhood usually resolve spontaneously with age, peanut sensitivity appears early in life and often persists indefinitely.

Frequently, large quantities of peanut allergens are not needed to elicit an allergic reaction- even trace levels of peanut are capable of causing a hypersensitive reaction.

The symptoms of peanut allergy vary from mild to severe, from swollen lips, shortness of breath to ananaphylactic shock, which is potentially fatal.

Mild to moderate symptoms are: Itchy skin or hives, which can appear as small spots or largewelts, an itching or tingling sensation in or around the mouth or throat, nausea, a runny or  congested nose.

– The most severe allergic reaction to peanuts is anaphylaxis, a life-threatening whole-body response to an allergen. Symptoms include impaired breathing, swelling in the throat, a sudden drop in blood pressure, pale skin or blue lips, fainting and dizziness.

“According to DelveInsight, Among the EU5 countries, France had the highest prevalent population of Peanut Allergy with 614,959 cases, followed by Germany and the United Kingdom. “

The launch of the emerging therapies is expected to significantly impact Peanut Allergy treatment scenario in the upcoming years:-
Drugs covered

  1. Palforzia
  2. Viaskin Peanut
  3. ANB020
  4. Omalizumab

And many others

The key players in Peanut Allergy market are:

  1. Aimmune Therapeutics
  2. DBV Technologies
  3. AnaptysBio
  4. Genentech

And many others

Request for sample pages : https://www.delveinsight.com/sample-request/peanut-allergy-market

Table of contents

1. Key Insights

2. Peanut Allergy: Market Overview at a Glance

2.1. Total Market Share (%) Distribution of Peanut Allergy in 2017

2.2. Total Market Share (%) Distribution of Peanut Allergy in 2030

3. Peanut Allergy: Disease Background and Overview

3.1.1.Introduction

3.1.2.Peanut Allergen

3.1.3.Characterization of Peanut Allergens

3.2. Clinical Presentation

3.2.1.Clinical Symptoms

3.3. Causes and Risk Factors

3.3.1.Risk Factors

3.4. Pathophysiology of Peanut Allergy

3.5. Cross-reactivity with Other Foods

3.5.1.Outgrowing Peanut Allergy

3.6. Diagnosis of Peanut Allergy

3.6.1.History, the key Diagnostic Test

3.6.2.Skin Prick Tests (SPT)

3.6.3.Serum Peanut-IgE Concentration

3.6.4.Component Testing

3.6.5.Peanut-Induced Anaphylactic Reactions

4. Epidemiology and Patient Population

4.1. Key Findings

5. Total Prevalent Population of Peanut Allergy in 7MM

6. United States Epidemiology

6.1. Assumptions and Rationale

6.2. Total Prevalent Population of Peanut Allergy in the United States (2017–2030)

6.3. Gender-Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)

6.4. Age-Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)

6.5. Severity–Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)

7. EU5 Epidemiology

7.1. Germany Epidemiology

7.1.1.Assumptions and Rationale

7.1.2.Total Prevalent Population of Peanut Allergy in Germany (2017–2030)

7.1.3.Gender-Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)

7.1.4.Age-Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)

7.1.5.Severity–Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)

7.2. France Epidemiology

7.2.1.Assumptions and rationale

7.2.2.Total Prevalent Population of Peanut Allergy in France (2017–2030)

7.2.3.Gender-Specific Prevalent Population of Peanut Allergy in France (2017–2030)

7.2.4.Age-Specific Prevalent Population of Peanut Allergy in France (2017–2030)

7.2.5.Severity–Specific Prevalent Population of Peanut Allergy in France (2017–2030)

7.3. Italy Epidemiology

7.3.1.Assumptions and Rationale

7.3.2.Total Prevalent Population of Peanut Allergy in Italy (2017–2030)

7.3.3.Gender-Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)

7.3.4.Age-Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)

7.3.5.Severity–Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)

7.4. Spain Epidemiology

7.4.1.Assumptions and Rationale

7.4.2.Total Prevalent Population of Peanut Allergy in Spain (2017–2030)

7.4.3.Gender-Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)

7.4.4.Age-Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)

7.4.5.Severity–Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)

7.5. United Kingdom Epidemiology

7.5.1.Assumptions and Rationale

7.5.2.Total Prevalent Population of Peanut Allergy in the UK (2017–2030)

7.5.3.Gender-Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)

7.5.4.Age-Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)

7.5.5.Severity–Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)

8. Japan Epidemiology

8.1.1.Assumptions and Rationale

8.1.2.Total Prevalent Population of Peanut Allergy in Japan (2017–2030)

8.1.3.Gender-Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)

8.1.4.Age-Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)

8.1.5.Severity–Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)

9. Treatment Algorithm, Current Treatment, and Medical Practices

9.1. Primary Prevention

9.2. Management

9.3. Oral Immunotherapy

9.4. Treatment Guidelines

9.4.1.Practice Guidelines for Peanut Allergies

10. Unmet Needs

11. Marketed Therapies

11.1. Palforzia: Aimmune Therapeutics

11.1.1.Product Description

11.1.2.Mechanism of Action

11.1.3.Regulatory Milestones

11.1.4.Safety and Efficacy

11.1.5.Clinical Trial Information

11.1.6.Advantages and Disadvantages

11.1.7.Product Profile

12. Emerging Therapies

12.1. Key Cross Competition

12.2. Viaskin Peanut: DBV Technologies

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

12.3. ANB020: AnaptysBio

12.3.1. Drug Description

12.3.2. Other Developmental Activities

12.3.3. Clinical Development

12.3.4. Safety and Efficacy

12.3.5. Product Profile

12.4. Omalizumab: Genentech

12.4.1. Drug Description

12.4.2. Other Developmental Activities

12.4.3. Clinical Development

12.4.4. Safety and Efficacy

12.4.5. Product Profile

Drug list continued..

13. Peanut Allergy: 7MM Market Analysis

13.1. Key Findings

13.2. Market Size of Peanut Allergy in 7MM (2017–2030)

14. United States: Market Outlook

14.1. United States Market Size

14.1.1. The total market size of Peanut Allergy

14.1.2. Market Size of Peanut Allergy by Therapies in the US

15. EU-5 countries: Market Outlook

15.1. Germany Market Size

15.1.1. The total market size of Peanut Allergy

15.1.2. Market Size of Peanut Allergy by therapies in Germany

15.2. France Market Size

15.2.1. The total market size of Peanut Allergy

15.2.2. Market Size of Peanut Allergy by therapies in France

15.3. Italy Market Size

15.3.1. The total market size of Peanut Allergy

15.3.2. Market Size of Peanut Allergy by therapies in Italy

15.4. Spain Market Size

15.4.1. The total market size of Peanut Allergy

15.4.2. Market Size of Peanut Allergy by therapies in Spain

15.5. United Kingdom Market Size

15.5.1. The total market size of Peanut Allergy

15.5.2. Market Size of Peanut Allergy by therapies in the UK

16. Japan Market Outlook

16.1. Japan Market Size

16.1.1. The total market size of Peanut Allergy

16.1.2. Market Size of Peanut Allergy by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Related Reports:

Peanut Allergy – Pipeline Insights, 2020

The Peanut Allergy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Peanut Allergy across the complete product development cycle, including all clinical and nonclinical stages.

Peanut Allergy – Epidemiology Forecast to 2030

The Peanut Allergy epidemiology covered in the report provides historical as well as forecasted Peanut Allergy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles